Anesthetic drugs & techniques

Unwanted spontaneous responsiveness and burst suppression in patients undergoing entropy-guided total intravenous anesthesia with target-controlled infusion: An observational prospective trial

J Clin AnesthPublished Prospective observational study

Authors' conclusion

The SE-SPI-guided TIVA-TCI did not prevent unwanted spontaneous responsiveness and BSupp.

Study context

Population
Adult (<65 years) and elderly (≥65 years) women undergoing breast surgery under propofol-remifentanil TIVA-TCI guided by state entropy (target 40–60) and surgical pleth index (target 20–50), without NMB
Participants
107 participants
Outcome
Incidence of unwanted spontaneous responsiveness and burst suppression (BSupp)
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Unwanted spontaneous responsiveness

13.1%

Burst suppression (BSupp)

45.8%

Observational data: associations, not effects.

Further findings

Unwanted spontaneous responsiveness: associations

Observed mainly in adults
P < 0.05
Higher CeP at return of responsiveness
P < 0.05

BSupp: associations

Lower median CeP during maintenance
P < 0.01
Lower CeP at return of responsiveness
P < 0.05

Remifentanil effect-site concentrations

Unwanted spontaneous responsiveness and BSupp not associated with significant differences in CeRs

Age-related hysteresis

Higher CeP at loss than at return of responsiveness
P < 0.001

Postoperative delirium (POD) (CAM-ICU)

Incidence of POD
12.2%
Only preoperative serum albumin associated with increased likelihood of POD
P = 0.046

Original publication

Unwanted spontaneous responsiveness and burst suppression in patients undergoing entropy-guided total intravenous anesthesia with target-controlled infusion: An observational prospective trial. J Clin Anesth. Published 19 January 2023. doi:10.1016/j.jclinane.2022.111045

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.